StockDuty ← Dashboard Nov 05, 2026 05:45 AM ET
SignalCorporate

NewAmsterdam Pharma GAAP EPS of -$0.14 beats by $0.30, revenue of $19.16M beats by $4.11M

NewAmsterdam Pharma beat EPS and revenue estimates by $0.30 and $4.11M.

What happened: NewAmsterdam Pharma (NAMS) reported Q3 GAAP EPS of -$0.14 and revenue of $19.16M, both above estimates. Key numbers: EPS -$0.14, beat by $0.30. Revenue $19.16M, up 5374.3% Y/Y, beat by $4.11M. Cash, cash equivalents and marketable securities $643.1M as of September 30, 2026, versus $728.9M as of December 31, 2025. Why it matters: Both the EPS and revenue figures came in ahead of consensus estimates, and revenue rose sharply year over year. Coverage: 4 outlets in 24h
NewAmsterdam Pharma (NAMS) reported Q3 GAAP EPS of -$0.14 and revenue of $19.16M, both above estimates.
Both the EPS and revenue figures came in ahead of consensus estimates, and revenue rose sharply year over year.
Sources